Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. - sprookjes - yvandenbroek - TriplyDB

Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria.

Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria.

http://www.wikidata.org/entity/Q34175404

about

Bariatric surgery and the kidney-much benefit, but also potential harm Urinary Stone Disease: Progress, Status, and Needs.Biodiversity and functional genomics in the human microbiome.Genome Sequence of Oxalobacter formigenes Strain HC-1 Hereditary causes of kidney stones and chronic kidney disease The colon: an overlooked site for therapeutics in dialysis patients.The genetic composition of Oxalobacter formigenes and its relationship to colonization and calcium oxalate stone disease Primary and secondary hyperoxaluria: Understanding the enigma Analysis of commercial kidney stone probiotic supplements.Oxalate-degrading microorganisms or oxalate-degrading enzymes: which is the future therapy for enzymatic dissolution of calcium-oxalate uroliths in recurrent stone disease?The role of the microbiome in kidney stone formation.Bifidobacterium animalis subsp. lactis decreases urinary oxalate excretion in a mouse model of primary hyperoxaluria Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1.Hyperoxaluria leads to dysbiosis and drives selective enrichment of oxalate metabolizing bacterial species in recurrent kidney stone endures.Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice.Gut microbiota and oxalate homeostasis.An update on primary hyperoxaluria.Hyperoxaluria and systemic oxalosis: an update on current therapy and future directions.Update on oxalate crystal disease.Kidney stone incidence and metabolic urinary changes after modern bariatric surgery: review of clinical studies, experimental models, and prevention strategies.Primary hyperoxalurias: diagnosis and treatment.Oxalobacter formigenes colonization normalizes oxalate excretion in a gastric bypass model of hyperoxaluria.The role of intestinal oxalate transport in hyperoxaluria and the formation of kidney stones in animals and man.Oxalobacter formigenes-associated host features and microbial community structures examined using the American Gut Project.LRLSHMDA: Laplacian Regularized Least Squares for Human Microbe-Disease Association prediction.A novel approach based on KATZ measure to predict associations of human microbiota with non-infectious diseases.Probiotic properties of Oxalobacter formigenes: an in vitro examination.Update on the evaluation of repeated stone formers.In vitro degradation of oxalate by recombinant Lactobacillus plantarum expressing heterologous oxalate decarboxylase.Comparative faecal microbiota of dogs with and without calcium oxalate stones.A novel approach for predicting microbe-disease associations by bi-random walk on the heterogeneous network.siRNA Therapeutics for Primary Hyperoxaluria: A Beginning.Secretion of biologically active heterologous oxalate decarboxylase (OxdC) in Lactobacillus plantarum WCFS1 using homologous signal peptides.A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria.A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria.Presence of Oxalobacter formigenes in the intestinal tract is associated with the absence of calcium oxalate urolith formation in dogs.Quantitative analysis of colonization with real-time PCR to identify the role of Oxalobacter formigenes in calcium oxalate urolithiasis.Nephrolithiasis and Nephrocalcinosis in Childhood-Risk Factor-Related Current and Future Treatment Options.Efficacy of Hydroxy-L-proline (HYP) analogs in the treatment of primary hyperoxaluria in Drosophila Melanogaster.BMCMDA: a novel model for predicting human microbe-disease associations via binary matrix completion

P2860

Q26850597-51204473-F6C1-4A49-BE95-4F0483E897BE Q30373434-8622D3D0-29BD-463B-84D2-5E5B8F2388D9 Q31106599-27D3FFD1-3E14-4429-868A-FA2987EF2111 Q33887506-5AACD752-4F76-4925-814E-E7FD4C9C2C9E Q34066169-FD84677E-0FE9-4820-9F75-27901560F579 Q34607428-4889E319-62B8-44D5-BDA9-9804C154610D Q34697330-6B5894CC-FCE0-4199-8C8B-2CA2F7E34094 Q35567868-1DE291EA-5419-4436-AACB-B9EB6D04B88F Q35570463-51259E69-DBEF-462B-883A-D8C55E35219D Q35863258-54ACF392-2087-4AA8-BA3A-359DE1B8B849 Q36193540-073DE518-BEF4-4752-A0F6-04060A091778 Q36239614-1CA263E1-5BDF-4331-9B28-BE042CE9F100 Q36951298-130837FD-94FB-4806-A731-8D8EB8E43A2E Q37314836-EDA3C952-459A-4D89-9FA1-B6FCCD1D335A Q37621553-419F7DC9-F8EE-43DB-928B-7FFA798D77B2 Q37634448-6720EB0A-F8B1-4D40-82C2-0485184B0B68 Q38017938-6BF4A1DD-FE65-4E77-B740-B9244443ECD8 Q38061207-9C28441A-0D86-4A28-930A-65C55AB3A6D3 Q38105961-D33A83EA-B270-4EBA-9076-72256ECA2AF4 Q38223535-0ABF2EF8-BA8F-41F4-A585-E0459DDCCE9C Q38292247-61F8D5EE-C6C8-48F6-A257-CB2AA4E010DC Q38404011-669851B5-5068-4E02-BAD0-F1B52021C958 Q38406458-97A73D74-A16D-469B-9A5F-9D9E580B0688 Q38607993-BBBEECB3-5F97-4D60-BAF0-5C05129BC0D5 Q38645220-2113C7D8-9C87-4FB3-9D21-807ABAEB8D7F Q39063472-59D42027-13F9-4A5A-99E8-6825739B36D3 Q39294414-5E31EEE7-B353-494A-BF38-77EEB5C36262 Q39405280-98C37AED-D4CA-42DA-8A64-BFEB3D7C4024 Q39407773-7DA09CD5-F166-43F9-A5D0-5455C690AC88 Q39587285-A113E0AE-B57C-428B-B5EB-4232646F4B3F Q41570635-14FEDCA4-E3D6-4334-94D2-29B286BF0E6A Q41840275-BBB33054-C5C5-403D-9DB8-28EB79B19A7E Q45901802-B40A5DEA-4832-44D5-87E4-9CF9BD4C63A5 Q51839463-A95FC12F-DAF1-4358-B55F-DFF2E698D13E Q52815916-C393AF86-1C4B-4AA5-BF6E-B3681C0459D8 Q54330633-01749592-B0FA-4429-8173-DBC31819D9F9 Q54331122-DD70095B-DE43-4211-B4A8-CFD4126B38BC Q55030066-896FB23C-9BE8-4C66-A6A4-CDC889784D20 Q55510373-7D439FDA-C308-44AC-9645-C11BCCE486DD Q58785511-E6D8BD75-93B9-4CAE-AD3E-3CCEF0AA7BEF

P2860

Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria.

http://www.wikidata.org/entity/Q34175404

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Efficacy and safety of Oxaloba ...... late in primary hyperoxaluria.

@ast

Efficacy and safety of Oxaloba ...... late in primary hyperoxaluria.

@en

Efficacy and safety of Oxaloba ...... late in primary hyperoxaluria.

@nl

type

label

Efficacy and safety of Oxaloba ...... late in primary hyperoxaluria.

@ast

Efficacy and safety of Oxaloba ...... late in primary hyperoxaluria.

@en

Efficacy and safety of Oxaloba ...... late in primary hyperoxaluria.

@nl

prefLabel

Efficacy and safety of Oxaloba ...... late in primary hyperoxaluria.

@ast

Efficacy and safety of Oxaloba ...... late in primary hyperoxaluria.

@en

Efficacy and safety of Oxaloba ...... late in primary hyperoxaluria.

@nl

P1433

Q34175404-6C5C8422-6151-4843-B31B-422B7C9DBD3F

P1476

Q34175404-36DBCE88-65F0-4995-8C44-DE8F7A9E2DC1

P2093

Q34175404-1B39D98B-F07A-4E43-BF6B-23E8648F1D0A

Q34175404-1FE71FA3-8AA4-453D-9FAE-DE6002E13E5C

Q34175404-32395A76-A03F-4173-AAC8-DBF2FA7ECA45

Q34175404-82439E51-3868-481F-A86A-F80DFC87383C

Q34175404-87ADD723-AE72-4907-BDAA-25A0B4505622

Q34175404-8D8692FC-6707-44E6-8B37-3719D6A7265F

Q34175404-CA83D7F6-A143-47E3-96FA-FCB6BF08FF68

Q34175404-E6ACD7D6-EB76-4E84-B0F6-0A1754966720

P2860

Q34175404-1AC83017-C90A-48ED-A374-36A6D57C314B

Q34175404-207F574C-CB3E-46C5-90CA-F04380958F50

Q34175404-21D885A8-4C2B-4C30-A832-96777D828D5D

Q34175404-26847D32-6A04-4303-9B23-A2D9390C1FC3

Q34175404-3549922C-E83E-4105-94EC-4A73B518CC17

Q34175404-407B9026-FE8C-4907-8FB7-4EFAD381868B

Q34175404-49D41467-435D-4B3E-AD61-60353A07073A

Q34175404-53310AEC-BED3-4010-A74B-06A16AAD72C1

Q34175404-7C0C0BF6-654F-4DCA-A3BC-610FF948A3F5

Q34175404-88D43FAF-257D-41AE-BC97-54E7AD4508A8

P304

Q34175404-B8693A9D-D6C6-4538-93F2-50B18E801548

P31

Q34175404-9423180C-C3CD-4259-AB44-86A726635DA7

P356

Q34175404-A7FA03A2-3360-41CB-8488-2E8E8B91F8EC

P407

Q34175404-EF8CBE62-6918-45AD-A6B4-D3A2DFBFD750

P433

Q34175404-8BAEF651-132B-47B0-A7F9-67DDE816DA7F

P478

Q34175404-A4CE6941-EF61-4D66-96A8-AB692E080594

P50

Q34175404-3FA0B254-CA22-427A-B7BF-815BE9FA75CF

P577

Q34175404-ADD89B0F-FD4A-41B7-9A73-A16A8F467BD1

P5875

Q34175404-2178524C-737D-458C-A9D4-05130827543F

P698

Q34175404-DBBD5A73-500C-4E36-87E5-D0A434073744

P356

P1433

Nephrology Dialysis Transplantation

P1476

Efficacy and safety of Oxaloba ...... alate in primary hyperoxaluria

@en

P2093

Bernd Hoppe

http://www.w3.org/2001/XMLSchema#string

Dawn Milliner

http://www.w3.org/2001/XMLSchema#string

Jaap W Groothoff

http://www.w3.org/2001/XMLSchema#string

Markus J Kemper

http://www.w3.org/2001/XMLSchema#string

Patrick Niaudet

http://www.w3.org/2001/XMLSchema#string

Pierre Cochat

http://www.w3.org/2001/XMLSchema#string

Robert Unwin

http://www.w3.org/2001/XMLSchema#string

Sally-Anne Hulton

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations in DHDPSL are responsible for primary hyperoxaluria type III

Molecular etiology of primary hyperoxaluria type 1: new directions for treatment

Molecular analysis of the glyoxylate reductase (GRHPR) gene and description of mutations underlying primary hyperoxaluria type 2.

Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with Oxalobacter

Primary hyperoxaluria type 1 in The Netherlands: prevalence and outcome.

Intestinal transport of an obdurate anion: oxalate.

Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele.

International registry for primary hyperoxaluria.

Oxalobacter formigenes gen. nov., sp. nov.: oxalate-degrading anaerobes that inhabit the gastrointestinal tract.

Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones.

P304

3609-3615

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NDT/GFR107

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

Georges Deschenes

P577

2011-04-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50989252

http://www.w3.org/2001/XMLSchema#string

P698

21460356

http://www.w3.org/2001/XMLSchema#string